PubMed · 15593008
Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir.
Abstract
The availability of valganciclovir (VGCV) has significantly simplified the treatment of human cytomegalovirus (HCMV) infection after solid-organ transplantation. We show that there was no difference in the kinetics of the decrease in HCMV load after preemptive therapy with VGCV in 22 solid-organ transplant recipients (T1/2=2.16 days), compared with that in 23 patients treated with intravenous ganciclovir (GCV) (T(1/2) = 1.73 days; P=.63). Preemptive therapy with VGCV provides control of HCMV replication that is comparable to that achieved with preemptive intravenous therapy with GCV.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
F M Mattes, E G Hainsworth, A F Hassan-Walker, A K Burroughs, P Sweny, P D Griffiths, V C Emery. 2004-11-29. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir.. https://doi.org/10.1086/425905. https://pubmed.health/record/pubmed%3A15593008/kinetics-of-cytomegalovirus-load-decrease-in-solid-organ-transplant-recipients-after-preemptive-ther
Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite PubMed Health by Indiciae: BibTeX · RIS.